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Carotid endarterectomy (CEA) has emerged as the
currently preferred treatment of symptomatic1-3 and
asymptomatic4,5 patients with high-grade extracranial
carotid stenoses. Symptomatic or asymptomatic
carotid restenosis (CR) after endarterectomy is rela-
tively uncommon and is generally attributed to myoin-
timal hyperplasia during the early postoperative period
(within 36 months) or recurrent atherosclerosis there-
after.6-10 Surgical management of carotid restenosis is
controversial for two major reasons. First, indications
for operative management in the asymptomatic patient
with high-grade (80% or greater) restenosis are applied
conservatively by some, because of the low risk of
Carotid restenosis: Operative and
endovascular management
Robert W. Hobson II, MD, Jonathan E. Goldstein, MD, Zafar Jamil, MD,
Bing C. Lee, MD, Frank T. Padberg, Jr, MD, Abigail K. Hanna, MD, Gary
A. Gwertzman, MD, Peter J. Pappas, MD, and Michael B. Silva, Jr, MD,
Newark, NJ
Purpose: Surgical management of carotid restenosis (CR) after carotid endarterectomy
(CEA) has been associated with a higher perioperative complication rate than that of pri-
mary CEA. We recently used carotid angioplasty-stenting (CAS) as an alternative to
operative management in patients who had undergone CEA within three years, and we
retrospectively compared these results with those of operative management of CR and
the overall results of CEA. 
Methods: CEA was performed on 1065 adult patients (58% symptomatic, 42% asympto-
matic), 62% of whom were men (n = 660) and 38% of whom were women (n = 405),
from 1989 to 1997. Before our initiation of a program of CAS, 16 operative procedures
(1.9% of CEAs) were performed for CR in 14 adult patients (7 women and 7 men).
During the last 20 months, CAS was used in the management of 17 CRs (16 patients;
9 women and 7 men). 
Results: The 30-day stroke morbidity-death rate for all CEAs (n = 1065) was 1.4%; 11
strokes (1.0%) occurred (4 major strokes with disability and 7 strokes with minor or no
disability), and 4 deaths (0.4%) occurred (2 deaths caused by myocardial infarction, 1
caused by intracranial hemorrhage, and 1 caused by stroke). Operative management of
CR (n = 16) included patch angioplasty in 12 cases (autologous vein patches in 10 cases
and synthetic patches in 2 cases), whereas interposition grafting was used in 4 cases
(saphenous vein in 3 instances and synthetic [polytetrafluoroethylene] in one case). No
strokes or deaths were observed. One recurrent laryngeal nerve palsy occurred (6.2%).
Among the 16 patients undergoing 17 CAS procedures, the technical procedures were
accomplished in all patients. No strokes or deaths occurred. No recurrent restenoses
(50% or greater) have been identified within or adjacent to the CAS procedures.
Conclusion: CR caused by myointimal hyperplasia can be managed by operative tech-
niques or CAS with comparable periprocedural complications. Although long-term fol-
low-up will be required to determine the incidence of recurrent restenosis, CAS may
become the preferred procedure in these cases. A randomized clinical trial ultimately will
be necessary to determine the role of CAS, as compared with that of operative manage-
ment. (J Vasc Surg 1999;29:228-38.)
From the Division of Vascular Surgery, and the Division of
Cardiology (Dr Goldstein), St. Michael’s Medical Center and
University of Medicine and Dentistry of New Jersey–New
Jersey Medical School.
Presented at the Forty-sixth Scientific Meeting of the
International Society for Cardiovascular Surgery, North
American Chapter, San Diego, Calif, June 7–8, 1998.
Reprint requests: Robert W. Hobson II, MD, Division of
Vascular Surgery, Department of Surgery, UMDNJ-NJMS,
Medical Science Building, G-532, 185 South Orange Ave,
Newark, NJ 07103.
Copyright © 1999 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/99/$8.00 + 0 24/6/94796
JOURNAL OF VASCULAR SURGERY
Volume 29, Number 2 Hobson et al 229
stroke or progression to total occlusion.6,11,12
Second, reoperation is associated with a marginal-
ly increased risk of perioperative neurological
events and cranial nerve palsies.8,13,14 Because of
these issues, other authors15-20 recommend carotid
angioplasty-stenting (CAS) as an alternative to opera-
tive management. However, lack of efficacy data com-
paring endovascular management with carotid
endarterectomy has created additional controversy
about the choice of treatment among specialists seeing
patients with CR and those with primary atheroscle-
rotic occlusive disease.21,22
We prospectively collected data and intervened
with endovascular techniques on patients with symp-
tomatic and asymptomatic (80% or greater) CR
caused by myointimal hyperplasia to define technical
feasibility and periprocedural outcomes. We also ret-
rospectively analyzed our performance with opera-
tive management of carotid occlusive disease and
restenosis and compared these data with our recent
experience with CAS. 
METHODS AND MATERIALS
From 1989 to 1997, CEA was performed on
1065 adult patients; 62% were men (n = 660), with
a mean age of 65 years, and 38% were women (n =
405), with a mean age of 62.7 years. Symptomatic
lesions were observed in 58% of cases (n = 618), and
asymptomatic stenoses were observed in 42% (n =
447). In patients undergoing CEA for symptomatic
disease, 81% of the group had high-grade stenoses
(70% or greater), whereas 19% of patients had mod-
erate stenoses (50% to 69%). Among symptomatic
patients, amaurosis fugax and transient ischemic
attack (TIA) constituted the indications for CEA in
65% of patients, whereas stroke with minimal to
moderate disability was the indication for CEA in
the remaining 35% of patients. CEA was performed
in asymptomatic patients for stenoses 80% or greater
in 76% of patients and for stenosis of 60% to 79% in
24% of patients. Before we initiated a program of
CAS for restenosis, 16 operative procedures were
performed for CR in 14 adult patients (seven men
and seven women), with a mean age of 64.5 years.
Two patients had bilateral CRs, whereas 12 other
patients had unilateral restenotic lesions. Nine of the
lesions were symptomatic, and seven were asympto-
matic. Indications for the patients’ prior CEAs were
symptomatic disease in 10 cases and asymptomatic
stenoses in six cases. Patch angioplasty had been used
in nine of the 16 earlier operations, and primary clo-
sure had been used in seven procedures. Early oper-
ations were performed in nine patients (within 36
months of the original CEA), and thereafter in seven
patients (more than 36 months postoperatively). 
During the last 20 months (September 1996
through May 1998), 17 CRs (16 patients) were
identified and treated by CAS. All symptomatic and
asymptomatic (80% or greater) patients with CR
were treated with CAS, and no patients were treated
operatively during this period. One patient was
treated for bilateral restenoses after staged bilateral
Fig 1. A, Preprocedural stenosis in a symptomatic patient (patient 1, Table I) and B, Post-
carotid angioplasty-stenting result with an 8 · 20 mm WallStent demonstrated by means of
selective arteriograms.
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CEAs, whereas 15 patients were treated for unilater-
al restenoses. There were nine women and seven
men in this group, with a mean age of 66.3 years.
The mean interval between CEA and CAS was 13.7
months, with the earliest procedure performed 5
months after surgery and the latest performed 31
months after surgery. Eight patients had sympto-
matic restenoses (amaurosis fugax or TIA in seven
and stroke in one), and eight patients were asymp-
tomatic. Indications for their original CEAs were
seven symptomatic and nine asymptomatic high-
grade stenoses. More than half of these patients (n =
10, 11 recurrent stenoses) were referred from other
institutions. Data on these patients are summarized
in Table I.
Technical considerations in performance of CAS
are outlined in Table II. Examples of preprocedural
and postprocedural results (Figs 1 and 2) are pre-
sented and demonstrate placement of an 8 or 10 mm
· 20 mm WallStent (Schneider, Minneapolis, Minn).
In each case, 4 or 5 mm low-profile balloons were
used to initially dilate the lesions, followed by place-
ment of appropriately sized stents, with poststent bal-
loon dilatation to obtain the final result. Intravascular
ultrasound was used as a means of ensuring adequate
apposition of the stent to the arterial wall (Fig 3). In
these cases and all except one other case, stents were
placed across the carotid bifurcation, and patency of
all external and internal carotid arteries was demon-
strated by means of serial duplex ultrasound scan.
The patency of this patient’s internal carotid artery
after CAS was confirmed by means of a follow-up
color Doppler energy scan (Fig 4). 
Transfemoral cannulation was used in all except
one CAS procedure (Table II); in this case, a 70-
year-old woman had severe aortoiliac occlusive dis-
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Table I. Patients treated with carotid angioplasty-stent (CAS)
Interval between Indication for CAS
earlier carotid endarterectomy (S, symptomatic;
Patient number Age (years)/Sex and CAS (months) A, asymptomatic) Procedural complications
1 68/M 11 S None
2 67/M 13 A None
3 74/M 11 S Hypotension/bradycardia requir-
ing vasopressors · 3 to 4 hours
74/M 12 A None
4 70/F 8 S None
5 65/F 17 A None
6 68/F 22 A Hypotension/bradycardia 
(transient)
7 61/F 20 A None
8 65/F 14 S None
9 70/F 12 A None
10 50/F 5 S None; incomplete stent apposi-
tion in patch-dilated carotid 
artery
11 64/M 31 S None
12 70/F 10 S None; performed via common 
carotid cannulation
13 71/M 11 A None
14 70/M 12 S None
15 60/F 14 A None
16 68/M 10 A None
Table II. Protocol for carotid angioplasty-stent
(CAS) procedure
• Transfemoral 8F introducer sheath; direct carotid cannu-
lation in presence of severe aortoiliac disease; preproce-
dural aspirin and Ticlid.
• 0.035 in J-guidewire with moveable core to aortic arch;
heparinization to activated clotting time of 225 to 250.
• NH-2 Vitek catheter for cannulation of aortic arch
branches.
• 0.035 in coated Terumo long exchange guidewire to
external carotid artery.
• 8F (internal diameter) guide sheath 100 cm length to
common carotid artery proximal to lesion.
• 0.018 in guidewire to cross common-internal carotid
stenosis.
• 4 mm low-profile balloon for prestent dilatation.
• Deployment of 8 · 20 mm or 10 · 20 mm WallStent over
0.018 in wire.
• Poststent dilatation using 5 or 6 mm balloons.
• Intermittent hand-injection angiography during proce-
dure; use bony landmarks for balloon and stent place-
ments.
• Remove sheath once ACT is less than 150; continue
aspirin; Ticlid is discontinued three weeks after CAS.
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ease with symptomatic CR 10 months after CEA
(patient 12, Table I). The proximal common carotid
artery was explored in the operating room under
local anesthesia and cannulated using C-arm fluo-
roscopy for CAS, as has been recommended by
Diethrich.20 The CAS procedure was accomplished
successfully, and the cannulation site was repaired
with a vascular suture.
All patients underwent placement of a single stent;
however, one patient underwent CAS for multiple
carotid lesions. This 50-year-old white woman
(patient 10, Table I) had undergone CEA at another
institution for TIA five months before CAS.
Recurrent symptoms resulted in the identification, by
means of angiography, of a common carotid stenosis
at the aortic arch and an internal carotid stenosis dis-
tal to a restenotic lesion at the upper end of a saphe-
nous vein patch (Fig 5) used in the original CEA. In
this instance, the arch stenosis was dilated, and an
attempt made to place a Palmaz stent across the
lesion. However, the stent migrated into the common
carotid artery, and placement of a WallStent was
required to entrap the Palmaz stent and maintain
patency of the dilated arch stenosis (Fig 6,A). A
guidewire (0.018 in) was then passed across the prox-
imal and distal internal carotid stenoses. Each stenosis
was dilated with a low-profile balloon, and an 8 · 20
mm WallStent was placed from a position just above
the distal stenosis across the stenosis at the apex of the
vein patch extending into the patch-dilated internal
carotid artery (Fig 6,B). 
RESULTS
The 30-day stroke morbidity for all CEAs in this
series (n = 1065) was 1.0%; 11 strokes occurred (4
major strokes with disability [0.4%] and 7 instances
with minor or no disability [0.6%]), whereas the 30-
day perioperative mortality was 0.4% (two deaths
caused by myocardial infarction, one caused by
Fig 2. A, Preprocedural stenosis in an asymptomatic patient (patient 6, Table I) and B, Post-
carotid angioplasty-stenting result with a 10 · 20 mm WallStent shown by means of selective
arteriograms.
A B
Fig 3. Satisfactory apposition of the struts of a WallStent
to the arterial wall of the internal carotid artery confirmed
by means of intravascular ultrasound.
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intracranial hemorrhage, and one caused by stroke).
The 30-day combined stroke-death rate was 1.4%.
Transient cranial nerve palsies were observed in 3.5%
of procedures (n = 37). Five patients returned to the
operating room for evacuation of hematomas that
were not further complicated. Patch angioplasty was
used increasingly during the years of this clinical
series (1989, 44%; 1992, 62%; 1996 to 1997, 90%). 
Operative management of 16 carotid restenoses
in 14 patients included the use of patch angioplasty
in 12 cases associated with a second endarterectomy
in seven instances (autologous vein patches were
used in 10 cases, and synthetic patches were used in
two cases), whereas interposition grafting was used
in four cases (saphenous vein in three instances and
synthetic [polytetrafluoroethylene] in one case).
During the 30-day postoperative period, no strokes
or deaths were observed. One recurrent laryngeal
Fig 4. A satisfactory technical result during clinical follow-up (patient 1, Table I) after carotid
angioplasty-stenting demonstrated by means of a color Doppler energy scan.
Fig 5. A, Stenosis of the left common carotid artery (arrow) at the aortic arch, and B, resteno-
sis of the upper aspect of an autologous vein patch closure (arrow) and a second distal internal
carotid stenosis (arrow) shown by means of procedural arteriograms (patient 10, Table I).
A B
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nerve palsy (6.2%) occurred. Although the patient’s
voice improved during the six months postopera-
tively, persistent cord palsy with movement of the
cord to the midline was observed by means of indi-
rect laryngoscopy. During a mean follow-up of 30
months, no deaths were reported; one patient
(6.2%) sustained a minor stroke caused by carotid
occlusion after an earlier demonstration of a patent
postoperative artery, and an asymptomatic recurrent
restenosis of 60%, which is being reevaluated for
progression every six months by means of duplex
ultrasound scan, developed in one patient (6.2%).
In 16 patients undergoing 17 CAS procedures,
the technical protocol for CAS (Table II) was
accomplished in all patients. Immediate postproce-
dural hypotension and bradycardia were observed in
2 of 17 procedures (12%). One patient became
hypotensive to a systolic pressure of 90 to 110 mm
Hg in a period of 3 to 4 hours and required intra-
venous vasopressors, whereas the other patient
responded to an additional dose of Atropine without
requiring pressor agents. No additional sequelae
occurred in these patients, and all patients were dis-
charged on the first day after the CAS procedure.
During the 30-day periprocedural period, no neuro-
logical complications or deaths occurred. During the
clinical follow-up (mean, 11 months), patients
underwent duplex ultrasound scan at three-month
to six-month intervals. No external carotid arteries
thrombosed during the postprocedural period.
Restenosis was identified in one patient as a 40% area
reduction within the midportion of the stent; fur-
ther intervention was not recommended. The one
patient undergoing placement of two separate
stents, one at the aortic arch and one at the internal
carotid artery, demonstrated poor apposition of the
stent to the arterial wall in the distal portion of the
patch-dilated internal carotid artery. Malpositioning
of the stent was confirmed by means of a follow-up
duplex scan (Fig 7); however, no thrombus or inti-
mal hyperplastic response was observed during the
initial follow-up period. 
DISCUSSION
CR after endarterectomy has been studied exten-
sively after an initial report on the low incidence of
symptomatic restenosis.7 Although absolute rates of
restenosis (50% or greater) have been documented to
occur in 6% to 14% of patients23-26 after CEA, accom-
panying neurological events have been reported in
only 1% to 5% of these patients. The incidence of
restenosis is variable and is in part dependent on the
definition of restenosis and the technique used to cal-
culate its incidence. DeGroote and associates27
emphasized the importance of using life-table meth-
ods as a means of determining the incidence of
restenosis. Calculation of an absolute restenosis rate
(arteries with restenotic lesions/total carotid proce-
Fig 6. A, Placement of the WallStent over the shorter Palmaz stent (arrows) with correction
of the aortic arch stenosis demonstrated by means of a postprocedural arteriogram (patient 10,
Table I). B, A second WallStent that was placed in the internal carotid after dilatation of prox-
imal and distal stenoses. A stenosis, which was not treated, is also seen in the left midsubcla-
vian artery. 
A B
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dures) will generally underestimate the incidence of
restenosis, because it is independent of the duration
and frequency of clinical follow-up. However, with
life-table methods, the probabilities of developing
restenosis (50% or greater) seven years after CEA has
been reported as 32% and 31% in two clinical
series.11,27 Regression of restenotic lesions also has
been defined by means of duplex ultrasound scan and
has been estimated to be as much as 10%.11 These
data emphasize the value of serial noninvasive testing
after CEA, particularly during the first few years post-
operatively. However, the heterogeneity of published
results on restenosis and operative complications28
suggests that much better data are needed if we are to
arrive at reliable estimates of these complications.
Although the risk of restenosis was highest during the
first few years after CEA and low thereafter, the rec-
ommended frequency of noninvasive testing after
CEA remains controversial.11,12,23,25,29 However, we
recommend noninvasive testing of patients at 6-
month to 12-month intervals during the first few
years after CEA. Thereafter, performance is based on
the development of cervical bruits and nonspecific or
lateralizing neurological symptoms, rather than rou-
tine screening. Patients with symptomatic or high-
grade (80% or greater) asymptomatic stenosis are then
referred for intervention.
We have restricted our clinical experience with
CAS to restenoses identified within three years of
CEA. Restenoses within this period are likely to be
hyperplastic stenoses, which are characterized by
smooth, generally nonulcerated surfaces. Although
we currently agree with the recent American Heart
Association Science Advisory30 that CAS should not
be used routinely for primary atherosclerotic disease
unless it is part of a clinical trial, expanding the use of
CAS to management of myointimal hyperplastic
restenoses seemed reasonable. Results from our series
confirm that CAS is safe and effective and that its
periprocedural complications are comparable with
operative intervention. Further follow-up will better
define the incidence of postprocedural recurrent
restenosis. Provided the recurrent restenosis rates are
low and their subsequent interventions by means of
endovascular methods are not associated with addi-
tional complications, CAS may become the preferred
treatment of myointimal hyperplastic restenoses. 
Operative management for CR was first outlined
by Stoney and String.7 These authors reported on
the treatment of 29 patients, 5 months to 13 years
after CEA. Second endarterectomies were performed
in 10 atherosclerotic restenoses, with vein patches
used in 8 additional cases; vein patches were used
alone in 10 instances, and vein graft replacement was
performed in six cases. One postoperative death
(3.4%) occurred because of stroke without other
complications in their series of patients. An expanded
series of 116 operations for restenosis in the same
Fig 7. Extension of the WallStent (arrow) into the venous patch-dilated internal carotid artery
demonstrated by means of a duplex scan (patient 10, Table I). Apposition of the stent to the
arterial wall was not achieved, and serial follow-up scans will be required.
institution was reported by Bartlett and colleagues8
and was accompanied by a 4.3% stroke morbidity,
with two deaths (1.7%) caused by stroke. Transient
cranial nerve palsies were reported in 23 cases
(19.8%). Das and colleagues14 reported the use of
patch angioplasty in 59 of 62 operations for resteno-
sis, with a combined stroke-death rate of 4.6% and an
incidence of transient cranial nerve palsies of 9.2%.
Although Gagne and associates31 reported no peri-
operative strokes or deaths in a series of 41 reopera-
tions, late postoperative neurological complications
or progression to occlusion occurred in 19.5% of
cases. The authors had no explanation for these find-
ings, but recommended close postoperative surveil-
lance. The results of interposition grafting for
replacement of the involved segment of carotid
artery also have been emphasized in recent years.
Treiman and co-authors13 used interposition saphe-
nous vein grafts in 57 of 162 operations for
restenoses performed between 1974 and 1991. The
use of vein grafting, however, resulted in a 3.5% peri-
operative stroke rate, as compared with 1.9% for sec-
ond CEAs. Edwards and colleagues32 used interposi-
tion vein grafts in 20 of 106 restenoses and reported
no strokes or deaths. Although no perioperative
strokes or deaths occurred in our series, higher stroke
and death rates have generally been reported in larg-
er series of patients undergoing reoperation, as com-
pared with primary CEA.
Analysis of the current clinical series was not
intended to provide data on the overall incidence of
restenosis, which has been studied previously by our
group27 and others,6-10 or to evaluate the impact of
technical considerations such as patch angioplasty.33-35
Rather, the purpose of this report was to introduce the
concept of CAS for the management of CR.
Experience and competency in endovascular manage-
ment of aortoiliac and femoropopliteal lesions has
been acquired by our vascular surgical group,36 and
our initial results of CAS appear to be comparable with
operative management. The level of experience
required to achieve technical proficiency with CAS also
has implications for future anticipated clinical trials
comparing CEA and CAS.37 Credentialling of inter-
ventionalists and vascular or neurosurgeons, who are
skilled in endovascular techniques in other vascula-
tures, probably requires performance of 15 to 30 CAS
procedures. Proctoring of initial cases by a cardiologist
or other competent interventionalist is an important
prerequisite to initiating a successful program in CAS. 
We thank Dr Robert D.G. Ferguson (previously at the
University of Tennessee and now head of the Department
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Dr Patrick J. O’Hara (Cleveland, Ohio). Dr Hobson
and colleagues describe a series of 16 patients with 17
early recurrent carotid stenoses, presumably caused by
myointimal hyperplasia, treated with angioplasty and
stenting, compared with a group of 14 patients with 16
recurrent stenoses treated with surgical repair. There were
no early strokes or deaths in either group. There was one
cranial nerve injury in the surgical group, one malposi-
tioned stent in the stented group, and one nonhemody-
namically significant recurrence in each. The authors con-
cluded that, for restenoses caused by myointimal hyper-
plasia, angioplasty and stenting is safe and effective and its
periprocedural complications are comparable with man-
agement by means of operative intervention. 
I share the authors’ view that angioplasty-stenting
probably will have a role in the management of carotid
occlusive disease, and this study demonstrates the feasibil-
ity of angioplasty-stenting in a small number of patients
with early recurrent carotid stenoses presumably caused by
myointimal hyperplasia. If these preliminary results are
borne out by other, larger studies, carotid angioplasty-
stenting may indeed become a welcome tool, especially if
it proves to be safe and effective for patients with neck
radiation or high lesions, who are difficult to treat with
traditional surgical methods. It clearly obviates the risk of
cranial nerve injury, which is nearly 10% after reoperations. 
The long-term results will be important, however. It
does seem counterintuitive that angioplasty-stenting
should be a durable solution for myointimal hyperplasia,
because this process is a recurring problem after angio-
plasty-stenting of the coronary and superficial femoral
arteries. 
This leads to my first question. Are the authors sure
that the lesions in both groups are comparable? Histologic
verification of myointimal hyperplasia in the stented group
is probably not feasible. Furthermore, 44% of the surgical-
ly treated restenoses occurred later than 36 months and,
therefore, likely were recurrent atherosclerosis. Did the
authors use any special pharmacologic methods to reduce
the chance of further recurrence in the stented group? 
My major reservation regarding this study, however,
has to do with the sample size. The authors acknowledge
this problem, which affects nearly all reports dealing with
recurrent carotid stenosis, because it is an uncommon
problem. I would caution against drawing firm conclu-
sions about the clinical equivalence of the two treatment
methods from this study, which seems really to be a pilot
study. For example, assuming an event rate of 5%, which
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approximates the 4.4% perioperative stroke rate we
observed in our own recent report, our statistician calcu-
lated that the power of the study reported today to detect
a difference in event rate from 5% to 10% at the usual 5%
confidence level is only 0.08. This means that the authors’
study had only about an 8% chance to detect such a dif-
ference if it really did exist. To reliably detect the same dif-
ference, a sample size of 900 patients, or about 450 in
each group, would be required. Consequently, I’d like to
ask the authors how confident they are that their conclu-
sions are really substantiated by their data.
Dr Robert W. Hobson II. Thank you, Dr O’Hara, for
your excellent comments and questions. Carotid resteno-
sis is relatively common, and your concerns about the 30%
or 35% restenosis rates after coronary stenting being trans-
lated to the carotids after these procedures needs to be
considered. However, I would suggest that the circula-
tions are probably not comparable. The carotid artery and
its cerebral circulation represent a low-resistance circuit
with an anatomically larger artery. Although the long-term
follow-up is unequivocally necessary, recurrent restenosis
rates may be lower after carotid stenting, as compared
with coronary stenting. 
This presentation describes a small sample size and
should be considered as a pilot study. It is not, in any way,
comparable with a randomized clinical trial. Furthermore,
your computation of sample size requirements is accurate.
In fact, it has been estimated that a clinical trial comparing
the efficacy of carotid endarterectomy and angioplasty-
stenting for atherosclerotic disease would require a sample
size as large as 2,200 procedures. Clearly, our sample of 33
restenoses managed by means of operative and endovascu-
lar techniques is not adequate to answer the question, and
yet these initial results are important when considering
options for patient care. I’m not suggesting that at this
time we proceed to refer patients for angioplasty, unless
the surgeon thinks the reoperative case would be associat-
ed with a higher risk. Of our 17 most recent cases, 10
patients (11 procedures) have been referred from other
institutions—a fair number of our colleagues are avoiding
reoperation in this group of patients. 
Regarding the periprocedural antiplatelet protocol,
patients receive aspirin and Ticlid for 48 hours before the
procedure, maintain both medications for three weeks,
and then continue with aspirin only. Other antiplatelet
agents may be available in the future, but, as far as I know,
they’ve never been tested or studied for carotid occlusive
disease. 
Again, I appreciate your comments about rushing to
judgment on a small sample size. We agree that surgical
management of this condition continues to yield excellent
results. We should be cautious about adopting this new
procedure. 
Thank you. 
Dr William D. Jordan (Birmingham, Ala). Thank you,
Dr Hobson. I enjoyed the presentation. I need to ask you
to consider some data that we presented at the Peripheral
Vascular meeting in January of this year, in which we
reviewed the UAB experience of 28 patients who had
angioplasty-stenting for recurrent stenosis. We had 5
events in that group that lasted more than 24 hours, so 5
strokes. All 5 of those patients were the recurrent variety
that was present greater than 5 years after their initial
endarterectomy. So, I can congratulate you on appropri-
ately selecting a better group. 
I would like to ask a question about the selection of
the early variety of recurrent stenosis, that is, less than 2
years. It took you basically 7 years to recruit patients in the
surgical group and come up with about 2 patients per year.
Now, if you look at the newer period, you recruited basi-
cally 12 patients a year, a much higher accrual rate. It
makes me wonder if we are falling prey to the “ocu-
lostenotic reflex” and dilating lesions that previously we
were watching, that is, dilating them only because they’re
there to see. 
Dr Hobson. Thank you for your comments. A higher
complication rate probably will be observed in patients
with carotid restenoses beyond 5 years. Because these
lesions are generally recurrent atheromas, artheroembolic
episodes should be more common and neurological event
rates should be higher. We have restricted our activities to
what we consider to be low-risk lesions that are probably
unassociated with ulceration in most instances. 
You also commented on the rapidity with which we
have acquired patients. The 16 operative procedures,
recruited from some 840 of 1065 endarterectomies per-
formed during the first five years of this reported clinical
experience constituted 1.9% of the surgical cases. However,
the 17 cases treated by means of angioplasty-stenting since
the fall of 1996 include six cases from our practice and 11
cases referred from other institutions. This accounts for the
differences in rates of recruitment, because the more recent
experience included the referral cases. 
Dr Kevin G. Burnand (London, UK). Dr Hobson,
I’m sure you know the question that I’m going to ask is
about the symptoms of the stenosis. How did you justify
recommending angioplasty-stenting to patients with
symptomless stenoses when you didn’t know the long-
term risks of the procedure? In a recent review in the
British Journal of Surgery in which we looked at all the
world literature, we could find very little evidence that
these patients went on to have any problems. Although it
was relatively straightforward, I presume, to enroll people
with symptomatic restenosis, how on earth did you get
them to consent to have a dilatation of a symptomless
restenosis? 
Dr Hobson. Thank you for your comments and ques-
tion. We are, of course, familiar with your review paper on
this topic in the British Journal of Surgery. You emphasized
a conservative approach to the asymptomatic patient with
carotid restenosis. Although no prospective data on the risk
of restenosis are available, we adopted a recommendation
for operative intervention when an asymptomatic restenosis
was an 80% or greater diameter-reducing stenosis. Based on
our results with operative intervention in these cases, we
regarded this as a reasonable decision, and therefore, we
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also decided to consider these patients for endovascular
interventions. Having established this threshold for opera-
tive intervention, we informed the patient of our recom-
mendation for operation or angioplasty-stenting. Typical of
our experience with aortoiliac occlusive disease, our patients
universally chose angioplasty. 
It is also our opinion that we are approaching clinical
equipoise on this question. As defined by Freedman
(Equipoise and the ethics of clinical research. N Engl J
Med 1987;317:141-5), when different specialists refer
their patients with the same disease for different treat-
ments, it may then be ethical to conduct a randomized
clinical trial that should document the incidence of
restenosis and its associated neurological events. Two
groups have submitted grant applications to the National
Institutes of Health to compare the efficacy of carotid
endarterectomy and angioplasty-stenting. Until such a
trial is conducted, recommendations for clinical manage-
ment will continue to be based on anecdotal data—that is,
your review suggesting conservative management and our
report recommending an operative or endovascular
approach. 
